Related Experiment Video
Updated: Sep 17, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
DHX34 deficiency triggers tumor-intrinsic immunity via a dsRNA-mediated type I interferon pathway activation in HCC
Chunli Zhang1, Limin Huang1, Zeyu Li1
1Department of General Surgery, National-Local Joint Engineering Research Center of Biodiagnostic & Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.
Abstract:
Tumors often evade immune surveillance by crippling their immunogenicity in the microenvironment. DHX34, an RNA helicase involved in nonsense-mediated mRNA decay pathway, is critical for aberrant RNA degradation. However, the effect of DHX34 in regulating the immunogenicity in hepatocellular carcinoma (HCC) is still unclear. Here, a surprising function of DHX34 in inhibited HCC immunogenicity is identified. DHX34-deficient tumors were infiltrated by activated T cells that impaired tumor growth and enhanced survival in mice. Mechanistically, DHX34 depletion triggered dsRNA accumulation which may activate cytosolic RNA-sensing pathway effectors such as MAVS, p-IKK, p-IRF3, and the subsequent type-I interferon response, evoking tumor-intrinsic immunity and leading to CD8 T activation. Collectively, DHX34 is implicated as a regulator that orchestrates a barrier in HCC by suppressing dsRNA-driven innate immune activation. Targeting DHX34 may enhance tumor immunogenicity and synergize with immunotherapies, offering a novel therapeutic strategy for HCC.
Insights
DHX34 depletion enhances hepatocellular carcinoma (HCC) immunogenicity by activating innate immune responses. This leads to T cell infiltration, impaired tumor growth, and improved survival in mice, suggesting DHX34 as a therapeutic target.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Tumors evade immune surveillance by reducing immunogenicity.
- DHX34, an RNA helicase, is crucial for mRNA decay.
- The role of DHX34 in hepatocellular carcinoma (HCC) immunogenicity is unknown.
Purpose of the Study:
- To investigate the function of DHX34 in regulating HCC immunogenicity.
- To explore DHX34's mechanism in controlling tumor immunity.
Main Methods:
- Analysis of DHX34-deficient HCC tumors in mice.
- Assessment of T cell infiltration and activation.
- Investigation of RNA sensing pathways and interferon response.
Main Results:
- DHX34 depletion led to T cell infiltration and impaired tumor growth in HCC mouse models.
- DHX34 deficiency caused dsRNA accumulation, activating cytosolic RNA-sensing pathways.
- This resulted in a type-I interferon response, tumor-intrinsic immunity, and CD8 T cell activation.
Conclusions:
- DHX34 suppresses dsRNA-driven innate immune activation in HCC, acting as a barrier to immunogenicity.
- Targeting DHX34 could enhance HCC immunogenicity and synergize with immunotherapy.
- DHX34 inhibition presents a potential novel therapeutic strategy for HCC.
Related Concept Videos
The Intrinsic Apoptotic Pathway
lncRNA - Long Non-coding RNAs
The Extrinsic Apoptotic Pathway
Abnormal Proliferation

